Evidence map›Paper›PMID 33125572›Full record

ArticleInflammation2021

Oridonin Attenuates TNBS-induced Post-inflammatory Irritable Bowel Syndrome via PXR/NF-κB Signaling.

Yun-Yun Shao, Yao Guo, Xiao-Juan Feng, Jun-Jin Liu, Zhuang-Peng Chang, Gui-Feng Deng, Ding Xu, Jian-Ping Gao, Rui-Gang Hou

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Anti-inflammatory effects of oridonin on anExperimental and therapeutic medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Frontiers in pharmacology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yun-Yun ShaoSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Yao GuoSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Xiao-Juan FengSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Jun-Jin LiuSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China. liujunjin326@163.com.
Zhuang-Peng ChangSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Gui-Feng DengSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Ding XuSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Jian-Ping GaoSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China. jpgao123@163.com.
Rui-Gang HouSchool of Pharmaceutical, Shanxi Medical University, Taiyuan, 030000, Shanxi, China. Ruiganghou9966@163.com.ORCID http://orcid.org/0000-0003-4245-8012
Shanxi Medical University · CN

Funding

Shanxi Basic Applied Research Program 201901D111389The Youth fund of the second affiliated hospital of Shanxi medical university 201802-1The Youth fund of the second affiliated hospital of Shanxi medical university 201902-2
6 · The paper itself

Abstract

To investigate the beneficial effects of oridonin, a diterpenoid compound isolated from Rabdosia rubescens, on the inflammatory response in TNBS-induced post-inflammatory irritable bowel syndrome (PI-IBS) model and the underlying mechanism. Using the PI-IBS rat model and Caco-2 cell lines, we found that intestinal barrier function reflected by lactulose/mannitol (L/M) ratio and tight junction protein level was significantly ameliorated by oridonin. We also demonstrated that oridonin abrogated inflammation through inhibiting the phosphorylation of NF-κBp65 as well as its downstream gene (iNOS, COX-2, IL-1β, and IL-6) level. Molecular docking studies confirmed the good binding activity between oridonin and PXR. In Caco-2 cell lines, oridonin markedly inhibited LPS-induced NF-κB activation in a PXR-dependent manner. Meanwhile, PXR and its target genes CYP3A4 and P-gp were induced by oridonin, which was associated with the decreased expression of NF-κB and the recovery of intestinal barrier. This study indicated that the therapeutic effect of oridonin on experimental PI-IBS through repairing intestinal barrier function may be closely associated with the regulatory role of PXR/NF-κB signaling pathway. Oridonin may serve as a PXR ligand for the development of drugs in the therapy for PI-IBS.

Indexed as

AnimalsAnti-Inflammatory AgentsBiomarkersBlotting, WesternCaco-2 CellsDiterpenes, KauraneHumansInflammationIrritable Bowel SyndromeMaleNF-kappa BPermeabilityPregnane X ReceptorRatsRats, Sprague-DawleyReal-Time Polymerase Chain ReactionAnti-Inflammatory AgentsBiomarkersDiterpenes, KauraneNF-kappa BoridoninPregnane X ReceptorTrinitrobenzenesulfonic Acidchronic low-grade inflammationintestinal barrier functionoridoninpost-inflammatory irritable bowel syndromePXR/NF-κB

Identifiers

PMID33125572
OpenAlexW3095592452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.